Group items tagged

This Funding Opportunity Announcement (FOA) invites research projects to improve understanding of the causes of high priority diseases in the United States and reducing/eliminating health disparities. Research is encouraged in the following high priority diseases within the scientific mission areas of the NIDDK: diabetes; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; sickle cell disease, specifically, studies in complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; hematologic diseases, including studies in abnormal hemoglobin synthesis; metabolic diseases; gastrointestinal, hepatic, and renal complications from infection with HIV. Clinical trials are not permitted in response to this FOA.

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions.  The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).  

The FOA encourages the submission of research project applications to determine nicotine's modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection.  Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.   

AOSSM, in partnership with Sanofi, offers a research grant program to fund investigations related to early osteoarthritis (OA) and/or prevention of OA progression. This grant reflects the growing recognition of the importance of osteoarthritis within sports medicine and orthopaedics. The grant will be for $50,000 to support either a clinical research study or a lab/basic science project. Proposed studies need not relate specifically to sports injuries and should also have broad applicability to OA in the general population.

The purpose of this FOA is to support an initial series of activities over a 3-year period to build the foundation for enhanced collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for beginning investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.

The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) is addressing patient safety and medication research by focusing on the safe usage of medications.  This perspective centers on how medications move through the health care system and how this systemic process can be improved so that patients are not harmed, while health care delivery is improved.  CQuIPS encourages the involvement of all members of the health care team, especially patients and families, nurses, pharmacists, technicians (pharmacy and medication administration technicians), health care administrators, risk managers, and physicians across all settings of care, including in the home. This FOA will fund investigative research demonstration projects that examine the effective implementation of processes, policies, and behaviors that support safe use of medication as well as its sustainment and dissemination.

This Funding Opportunity Announcement (FOA) invites applications for grant funding to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB)  

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.

This initiative will support research projects that implement and test comprehensive service approaches to engage and retain youth and young adults (age 12 - 25 years) from health disparity populations in the HIV Treatment Cascade, which includes diagnosis, linkage to care, engagement in care, retention in care, initiation of antiretroviral therapy (ART), and achievement of viral suppression.   

On September 13, WBI will be hosting its 3rd OEA Collider Event, this time on the topic of Human Performance Enhancement. Please block your calendars from 1:30 till 3:30 and plan to join us to learn more about the opportunities within this massive market space. For the purposes of this project, we're defining Human Performance Enhancement like this: As the world becomes more complex, the demands on human performance continue to increase. Athletic endeavors, military requirements, continuing independence into one's later years are all examples of market-driven needs for human performance enhancement. Strength, speed, endurance, vigilance, multi-tasking, mental-acuity, and recovery are all enhancement opportunities of interest. Formal evaluation of blue papers will begin on approximately 17 October 2016. Wright Brothers Institute continues to work diligently on our pilot project to refine a commercialization process for regional innovators. In March we had an OEA Collider event focused on the Precision Agriculture market which has resulted in 8 Blue Paper submissions and 2 on-going projects to commercialize several of the concepts explained in those blue papers. We're making significant progress toward providing real market solutions with a combination of several innovative technologies!

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs.

he U.S. Congress provides funds to CDC for programmatic support and procurement of vaccines critical to the success of the global initiatives for polio eradication and measles mortality reduction. The purpose of the program is to support the US Government-endorsed Global Polio Eradication Initiative, Global Measles Initiative, and the Global Immunization Vision and Strategy (GIVS) of which UNICEF is a key partner. Other key partners include CDC, World Health Organization (WHO), the Pan American Health Organization (PAHO), Rotary International, American Red Cross, and the UN Foundation. UNICEF, in conjunction with CDC, will provide programmatic assistance and vaccines for supplemental immunization activities (SIAs) in priority countries as well as strengthening of routine immunization delivery systems and capacities in developing countries to achieve globally agreed goals for disease eradication, elimination and reduction. Additionally this agreement may be used to support activities to address other global health priorities in line with CDC goals. Under this agreement, UNICEF will collaborate with CDC, World Health Organization (WHO), Rotary International, other partner agencies and national governments, for implementation of strategies to achieve the globally agreed goals of polio eradication, measles mortality reduction and elimination, and control of other vaccine preventable diseases (VPD), including identification and prioritization of country vaccine and programmatic assistance needs.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund), invites applications to support bioinformatics research training programs at low or middle income (LMIC) African country institutions with significant genomics research capacity.  African applicants may propose graduate degree and long term postdoctoral bioinformatics research training in collaboration with other African or high income country (HIC) collaborators.  It is expected that these training programs will address the need for bioinformatics research expertise in the H3Africa Consortium and result in sustainable centers of bioinformatics research training relevant to global health research for the African continent.

The NCI's Diversity Training Branch (DTB) and the Center to Reduce Cancer Health Disparities (CRCHD) announce the availability of the "Mentored Patient-Oriented Research Award to Promote Diversity" for career development of individuals with a health professional doctoral degree from groups currently underrepresented on a national level in the biomedical, clinical, behavioral, and social sciences. The NCI recognizes a unique and compelling need to promote diversity in the patient-oriented research workforce.   

This initiative aims to: (1) enhance our understanding of the multi-level factors that influence HIV prevention strategy use among adolescent girls and young women (AGYW) in sub-Saharan Africa and (2) develop and test novel interventions to address these factors and enhance the uptake and adherence to HIV prevention strategies among AGYW in sub-Saharan Africa.  The goal of this initiative is to look at the multiple levels of influence on AGYW's behavior from the individual level, to her partners, family members and peers as well as cultural, social norms and structural factors that may influence uptake and adherence to prevention strategies.     

The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare a number of individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC.

The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare a number of individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC.